Rafael Blasco

Dr. Rafael Blasco

Departamento de Biotecnología, INIA CSIC, Ctra. La Coruña km 7.5, E-28040 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1995 in Gene
Verified
Journal Article
Closed access
RBRafael Blasco
Rafael Blasco
BMBernard Moss
Bernard Moss

27 January 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
SDSophie Duraffour
Sophie Duraffour
MLMaría M. Lorenzo
María M. Lorenzo
GZGudrun Zöller
Gudrun Zöller
DTDimitri Topalis
Dimitri Topalis
DGDoug Grosenbach
Doug Grosenbach
RSRobert Snoeck
Robert Snoeck
ST-246 is one of the key antivirals being developed to fight orthopoxvirus (OPV) infections. Its exact mode of action is not completely understood, but it has been reported to interfere with the wrapping of infectious virions, for which F13L (peripheral membrane protein) and B5R (type I glycoprotein) are required. Here we monitored the appearance of ST-246 resistance to identify its molecular target. Vaccinia virus (VACV), cowpox virus (CPXV) and camelpox virus (CMLV) with reduced susceptibility to ST-246 were selected in cell culture and further characterized by antiviral assays and immunofluorescence. A panel of recombinant OPVs was engineered and a putative 3D model of F13L coupled with molecular docking was used to visualize drug–target interaction. The F13L gene of 65 CPXVs was sequenced to investigate F13L amino acid heterogeneity. Amino acid substitutions or insertions were found in the F13L gene of six drug-resistant OPVs and production of four F13L-recombinant viruses confirmed their role(s) in the occurrence of ST-246 resistance. F13L, but not B5R, knockout OPVs showed resistance to ST-246. ST-246 treatment of WT OPVs delocalized F13L- and B5R-encoded proteins and blocked virus wrapping. Putative modelling of F13L and ST-246 revealed a probable pocket into which ST-246 penetrates. None of the identified amino acid changes occurred naturally among newly sequenced or NCBI-derived OPV F13L sequences. Besides demonstrating that F13L is a direct target of ST-246, we also identified novel F13L residues involved in the interaction with ST-246. These findings are important for ST-246 use in the clinic and crucial for future drug-resistance surveillance programmes.

1 November 2001 in Journal of General Virology
Verified
Journal Article
Closed access
MGMarı́a M. Geada
Marı́a M. Geada
IGInmaculada Galindo
Inmaculada Galindo
MLMarı́a M. Lorenzo
Marı́a M. Lorenzo
BPBeatriz Perdiguero
Beatriz Perdiguero
RBRafael Blasco
Rafael Blasco
Vaccinia virus produces several forms of infectious virions. Intracellular mature virions (IMV) assemble in areas close to the cell nucleus. Some IMV acquire an envelope from intracellular membranes derived from the trans-Golgi network, producing enveloped forms found in the cytosol (intracellular enveloped virus; IEV), on the cell surface (cell-associated enveloped virus) or free in the medium (extracellular enveloped virus; EEV). Blockage of IMV envelopment inhibits transport of virions to the cell surface, indicating that enveloped virus forms are required for virion movement from the Golgi area. To date, the induction of actin tails that propel IEV is the only well-characterized mechanism for enveloped virus transport. However, enveloped virus transport and release occur under conditions where actin tails are not formed. In order to study these events, recombinant vaccinia viruses were constructed with GFP fused to the most abundant protein in the EEV envelope, P37 (F13L). The P37–GFP fusion, like normal P37, accumulated in the Golgi area and was incorporated efficiently into enveloped virions. These recombinants allowed the monitoring of enveloped virus movementsin vivo. In addition to a variety of relatively slow movements (<0·4 μm/s), faster, saltatory movements both towards and away from the Golgi area were observed. These movements were different from those dependent on actin tails and were inhibited by the microtubule-disrupting drug nocodazole, but not by the myosin inhibitor 2,3-butanedione monoxime. Video microscopy (5 frames per s) revealed that saltatory movements had speeds of up to, and occasionally more than, 3 μm/s. These results suggest that a second, microtubule-dependent mechanism exists for intracellular transport of enveloped vaccinia virions.

1 February 1989 in Virology
Verified
Journal Article
Closed access
RBRafael Blasco
Rafael Blasco
MAMontserrat Agüero
Montserrat Agüero
JRJose M. Almendral Del Rio
Jose M. Almendral Del Rio
EVEladio Viñuela
Eladio Viñuela


1 February 2000 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
Juan BárcenaJuan Bárcena
Juan Bárcena
MCMónica Morales Camarzana
Mónica Morales Camarzana
BVBelén Vázquez
Belén Vázquez
José Antonio BogaJosé Antonio Boga
José Antonio Boga
FPFrancisco Parra
Francisco Parra
JTJuan Maria Torres
Juan Maria Torres
We have developed a new strategy for immunization of wild rabbit populations against myxomatosis and rabbit hemorrhagic disease (RHD) that uses recombinant viruses based on a naturally attenuated field strain of myxoma virus (MV). The recombinant viruses expressed the RHDV major capsid protein (VP60) including a linear epitope tag from the transmissible gastroenteritis virus (TGEV) nucleoprotein. Following inoculation, the recombinant viruses induced specific antibody responses against MV, RHDV, and the TGEV tag. Immunization of wild rabbits by the subcutaneous and oral routes conferred protection against virulent RHDV and MV challenges. The recombinant viruses showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunization of contact uninoculated animals.